Why the study?
Following FDA authorization of a homologous Pfizer-BioNTech booster dose for children aged 5-11 years, further characterization of booster vaccination safety in this age group was needed.
Is the Pfizer-BioNTech COVID-19 vaccine third dose safe in children aged 5-11 years?
Is the Pfizer-BioNTech COVID-19 vaccine third dose safe in children aged 5-11 years?
A third dose of the Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years is well tolerated, with mostly mild-to-moderate local and systemic reactions and rare serious adverse events.
Answers are grounded in this paper and cite their sources.
Supports third-dose tolerability in children 5–11 years; extends surveillance data but leaves open confirmation in larger prospective studies.
On May 17, 2022, the Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine to authorize a homologous* booster dose for children aged 5-11 years 5 months after receipt of the second primary series dose (1) based on findings from a clinical trial conducted among 401 children aged 5-11 years (2). To further characterize the safety of booster vaccination in this age group, CDC reviewed adverse events and health impact assessments after receipt of a Pfizer-BioNTech third dose reported to v-safe, a voluntary smartphone-based safety surveillance system for adverse events occurring after COVID-19 vaccination, and adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), a passive vaccine safety surveillance system comanaged by CDC and FDA. During May 17-July 31, 2022, approximately 657,302 U.S. children aged 5-11 years received a third Pfizer-BioNTech dose (either a third primary series dose administered to immunocompromised children or a booster dose administered to immunocompetent children) ; 3,249 Pfizer-BioNTech third doses were reported to v-safe for children in this age group. Local and systemic reactions were reported to v-safe after a second dose and a third dose with similar frequency; some reactions (e.g., pain) were reported to be moderate or severe more frequently after a third dose. VAERS received 581 reports of adverse events after receipt of a Pfizer-BioNTech third dose by children aged 5-11 years; 578 (99.5%) reports were considered nonserious, and the most common events reported were vaccine administration errors. Three (0.5%) reports were considered serious; no reports of myocarditis or death were received. Local and systemic reactions were common among children after Pfizer-BioNTech third dose vaccination, but reports of serious adverse events were rare. Initial safety findings are consistent with those of the clinical trial (2).
No takes yet. Share an insight, caveat, or question.
Hause et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: